Idelalisib Approved to Treat Blood Cancers — Physician’s First Watch
Idelalisib Approved to Treat Blood Cancers
By the Editors
The FDA on Wednesday approved idelalisib (Zydelig) to treat patients with relapses of three types of blood cancer: chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma. The drug is an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase.